Coverage spread: 2 sources — 2 center
Lean ratings via AllSides / Media Bias-Fact-Check. How this works.
Where they agree
- Novo Nordisk shares fell roughly 6% despite the company raising its full-year 2026 sales and profit guidance.
- The oral Wegovy pill’s second-quarter revenue came in slightly below analyst expectations, contributing to the stock drop.
- Both note the guidance improvement itself, even if with different emphasis, as a genuine upgrade from Novo’s earlier, more pessimistic forecast.
- MarketWatch’s report is short and centers on the stock decline, mentioning the improved outlook only briefly and secondarily.
- CNBC gives detailed figures — specific guidance ranges, quarterly sales/profit numbers, and Wegovy pill prescription counts (5 million since January) — that MarketWatch omits.
- CNBC includes analyst commentary from Mizuho’s Jared Holz explaining the market’s reaction, a perspective absent from MarketWatch’s piece.
- CNBC ties the story to U.S. policy specifics (Medicaid coverage cuts, the “most favored nation” pricing deal with the Trump administration) and to competitive context with Eli Lilly’s upcoming earnings, details MarketWatch does not cover.
What Novo Nordisk reported
Novo Nordisk’s U.S.-traded shares dropped about 6% on Tuesday after the Danish drugmaker released updated 2026 guidance and preliminary second-quarter figures ahead of a fuller earnings report expected Wednesday. The company raised its full-year outlook, now projecting adjusted sales at constant exchange rates to range from down 6% to flat, an improvement from its earlier forecast of a 4% to 12% decline. It similarly upgraded its adjusted operating profit outlook to a range of down 6% to flat, also up from a prior forecast of a 4% to 12% drop.
For the second quarter, Novo said sales rose to 78.49 billion kroner (about $12.09 billion), up 3% in constant currency and up 7% on an adjusted basis. Adjusted operating profit climbed 11% in constant currency to 33.39 billion kroner.
The Wegovy pill’s miss
Despite the improved overall guidance, investors focused on a soft spot: Novo’s oral version of Wegovy, launched in January, brought in 3.22 billion kroner in the second quarter — just below the 3.27 billion kroner analysts had expected, according to StreetAccount. CEO Mike Doustdar said the pill has surpassed 5 million prescriptions since launch. Mizuho Securities healthcare analyst Jared Holz said the stock’s decline reflects a lack of upside in Wegovy pill sales relative to what models had projected, even though he characterized the quarter overall as an improvement in trajectory compared with earlier in the year.
Why the U.S. business is under pressure
Novo said it now expects a decline in U.S. sales, pointing to several factors: current prescription trends for GLP-1 injectable drugs, intensifying competition, and reduced obesity-medicine coverage under Medicaid. The company also cited lower realized prices in the U.S., partly a result of the “most favored nation” drug pricing agreement it struck with President Donald Trump covering its GLP-1 products.
The pill and a higher-dose injectable version of Wegovy have been central to Novo’s effort to regain ground in the GLP-1 weight-loss and diabetes drug market after rival Eli Lilly took a market-share lead with its Zepbound and Mounjaro injections. Eli Lilly is scheduled to report its own quarterly results on Wednesday, the same day Novo Nordisk is due to release its full earnings.
How the coverage differs
MarketWatch’s coverage is brief, framing the story mainly around the stock decline and noting only in passing that the company also revealed an improved annual outlook — its account emphasizes the drop first and treats the raised guidance as a secondary, almost contradictory detail. CNBC provides substantially more detail, laying out the specific guidance figures, the quarterly sales and profit numbers, the pricing agreement with the Trump administration, and an analyst’s on-the-record explanation for why the stock fell even as the underlying numbers improved. CNBC also situates the news within the competitive dynamic with Eli Lilly and notes the timing of both companies’ upcoming earnings releases, context that MarketWatch’s shorter piece does not include.
Why this matters for the GLP-1 market
Novo Nordisk’s stock reaction illustrates how sensitive investors have become to granular performance signals within the broader GLP-1 drug boom, even when a company’s headline guidance improves. The miss on Wegovy pill revenue, though a relatively small shortfall against analyst expectations, was enough to overshadow an upgraded full-year sales and profit outlook. The results also underscore how U.S. policy — including Medicaid coverage changes and the pricing deal tied to the “most favored nation” framework — is now a direct factor shaping obesity-drug revenue, alongside competitive pressure from Eli Lilly’s injectable products. With Eli Lilly’s earnings due the same day as Novo’s fuller report, the market will get a fresh read on how the two companies’ market shares and pricing strategies are shifting in one of pharma’s fastest-growing categories.
Sources
Featured photo: News Øresund – Johan Wessman via Wikimedia Commons (CC BY 3.0)